Hippocampal ProNGF Signaling Pathways and β-Amyloid Levels in Mild Cognitive Impairment and Alzheimer Disease

Elliott J. Mufson, PhD, Bin He, MD, Muhammad Nadeem, MD, Sylvia E. Perez, PhD, Scott E. Counts, PhD, Sue Leurgans, PhD, Jason Fritz, PhD, James Lah, MD, Stephen D. Ginsberg, PhD, Joanne Wuu, MS, and Stephen W. Scheff, PhD

1Department of Neurological Science, Rush University Medical Center, Chicago, Illinois

2Rush Alzheimer’s Disease Center, Chicago, Illinois

3Center for Neurodegenerative Disease and Department of Neurology, Emory University, Atlanta, Georgia

4Center for Dementia Research, Nathan Kline Institute, Orangeburg, New York, and Departments of Psychiatry, and Physiology & Neuroscience, New York University Langone Medical Center, New York, New York

5Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida

6Sanders-Brown Center on Aging, University Kentucky College of Medicine, Lexington, Kentucky

Abstract

Hippocampal precursor of nerve growth factor (proNGF)/NGF signaling occurs in conjunction with β-amyloid (Aβ) accumulations in Alzheimer disease (AD). To assess the involvement of this pathway in AD progression, we quantified these proteins and their downstream pathway activators in postmortem tissues from the brains of subjects with no cognitive impairment (NCI), mild cognitive impairment (MCI), and AD using immunoblotting and enzyme-linked immunosorbent assay (ELISA). Hippocampal proNGF was significantly greater in AD compared to NCI and MCI cases. TrkA was significantly reduced in MCI compared to NCI and AD, whereas p75NTR, sortilin, and neurotrophin receptor homolog-2 remained stable. Akt decreased from NCI to MCI to AD, whereas phospho-Akt and phosphor-Akt to Akt ratio were elevated in AD compared to MCI and NCI. No differences were found in phospho-Erk, Erk or their ratio across groups. c-jun kinase (JNK) remained stable across groups, while phospho-JNK and the phospho-JNK to JNK ratio increased significantly in AD compared to NCI and MCI. Expression levels of Aβ1-40, Aβ1-42 and Aβ40/42 ratio were stable. Statistical analysis revealed a strong positive correlation between proNGF and phospho-JNK, though only proNGF was negatively correlated with cognitive function and only TrkA was negatively associated with pathologic criteria. These findings suggest that alterations in the hippocampal NGF signaling pathway in MCI and AD favor proNGF-mediated pro-apoptotic pathways, and that this is independent of Aβ accumulation during AD progression.
Keywords
Alzheimer disease; Amyloid; Mild cognitive impairment; Nerve growth factor; proNGF; Protein kinases, TrkA

INTRODUCTION
The hippocampus, a critical node of the episodic memory network, is one of the first brain sites to develop neurodegenerative changes in living individuals at risk for dementia as well as those with a clinical diagnosis of mild cognitive impairment (MCI), a prodromal stage of Alzheimer disease (AD), or AD (1, 2). Despite the expression of early degenerative events, the hippocampus displays remarkable evidence for neuroplasticity during the prodromal phase(s) of AD. For example, the activity of choline acetyltransferase, the rate-limiting enzyme for acetylcholine synthesis, is increased in the hippocampus of people with MCI (3, 4), suggesting that this region is resilient to the stress of disease onset via increased input from cholinergic neurons of the septal/diagonal band. Because damage to this pathway plays a key role in memory and attentional dysfunction during AD progression (5-7), understanding the signaling events that underlie septohippocampal plasticity are crucial for delineating the mechanisms that cause reactive synaptogenesis in this region and may provide translational information for the development of novel treatment strategies to promote cholinergic neuroplasticity over the extent of AD.

A central concept underlying the integrity of the cholinergic septohippocampal projection system is the observation that mature nerve growth factor (NGF), its pro form (proNGF) (8), and their cognate receptors play a crucial role in the function of this pathway and that their dysregulation contributes to degeneration of this projection system in AD (7). Mature NGF binds primarily to the TrkA receptor, which stimulates survival signal transduction pathways (5, 9). However, the binding of p75 neurotrophin receptor (p75NTR) to proNGF has multiple functions including pro-apoptotic and/or cell death actions (10), which are dependent upon its interaction with co-receptor chaperones including sortilin and neurotrophin receptor homolog-2 (NRH2) (8, 10-14). NGF/proNGF receptor binding activates downstream protein kinase signaling pathways involved in pro-cell survival and pro-cell death actions (15-18) including Erk and protein kinaseB/Akt (which activate intracellular events responsible for neuronal survival and neurite differentiation [16, 19]), as well as the c-jun kinase (JNK)-mediated pro-apoptotic pathway (20). Although data suggest a close relationship between β-amyloid (Aβ) and NGF receptor signaling in AD (21, 22), it remains to be determined whether alterations in hippocampal proNGF signaling track with changes in Aβ levels during the onset of AD. In fact, the majority of studies on proNGF/NGF signaling have been performed on cellular or animal models of cerebral amyloid overexpression, not on bona fide human AD brain tissues.

To characterize whether AD disease progression affects the expression level of these cell survival and pro-apoptotic pathways within the hippocampus relative to Aβ deposition, (23), we examined tissue harvested from people who died with a premortem clinical diagnosis of no cognitive impairment (NCI), MCI or AD using Western blot and ELISA technology and correlated these findings with cognitive and neuropathologic variables.

MATERIALS AND METHODS
Subjects
This study included 37 cases with an antemortem clinical diagnoses of NCI (n = 11, 6F/5M, mean age at death ± SD = 83.4 ± 4.6 years, Mini-Mental State Examination [MMSE] 27.6 ±
1.4), MCI (n = 13, 8F/5M, 85.4 ± 4.0 years, MMSE 27.5 ± 2.5) and AD (n = 13, 7F/6M, 87.7 ± 5.8 years, MMSE 19.9 ± 6.4) from the Rush Religious Order Study (RROS) (Table 1) (24-26). Each participant had agreed to an annual detailed premortem clinical evaluation and brain donation at the time of death. An additional 7 NCI (6F/1M, 83.7 ± 6.4 years, 28.3 ± 2.4), 5 MCI (3F/2M, 87.4 ± 3.9 years, MMSE 25.8 ± 3.3), and 5 AD (2F/3M, 84.8 ± 8.0 years, MMSE 13.2 ± 7.9) cases were obtained from the University of Kentucky ADC Brain Bank and used to measure NRH2 protein levels, which were only available in a subset of the RROS cases (5 NCI, 4 MCI, and 6 AD). The Human Research Committees of Rush University Medical Center and the University of Kentucky approved this study. Written informed consent for research and autopsy was obtained from study participants or their family/guardians.

Clinical and Neuropathological Evaluation

Details of the clinical evaluation and criteria for diagnosis of AD and MCI in the RROS cohort have been published elsewhere (24, 26, 27). There was an average time of ~8 months between death and the last clinical and neuropsychological evaluation, which included the MMSE and a battery of 19 cognitive tests. A Global Cognitive Score (GCS), a composite z-score that indicates overall cognitive function, was compiled from the 19 tests. An episodic memory z-score, which is more specific for hippocampal function, was also computed based on 7 of the tests. Among the RROS MCI cases, 4 were amnestic MCI, whereas all MCI cases from University of Kentucky ADC were amnestic MCI based upon a clinical dementia rating score of 0.5 (28). For both populations, a final clinical diagnosis was assigned after consensus conferences of neurologists and neuropsychologists who reviewed all relevant data and information collected. Neuropathological diagnosis was performed as previously described (24, 26, 27) and included Braak staging of neurofibrillary tangles (NFTs) (29), the NIA-Reagan criteria (30), and recommendations of the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) (31). Subjects with pathological findings other than AD (e.g. stroke, Parkinson disease, Lewy body dementia) were excluded from the study. None of the cases examined was treated with anticholinesterase inhibitors. Clinical, demographic and neuropathological details of the RROS cases are presented in Table 1. Tissue and clinical information is under the protection of the Health Information Privacy Administration rules.

Tissue Samples

Hippocampal samples were dissected free of white matter at autopsy in the coronal plane at the level of lateral geniculate nucleus (which included all layers and cell types of this structure) on dry ice to prevent thawing of the tissue, and were frozen at −80°C until the time of biochemical assay. Frozen hippocampus was homogenized (150 mg/ml) on ice in phosphate-buffered saline and immediately divided into 2 aliquots. One aliquot was added to a homogenization buffer (250 mM sucrose, 20 mM Tris base) containing protease inhibitors (100× protease inhibitor cocktail, cat. #8340, Sigma, St. Louis, MO) and divided into 2 aliquots: one was used for the Aβ ELISA, and the second aliquot was diluted to 10 mg tissue/ml with potassium phosphate-buffered saline, pH 7.4 for Western blotting.

Antibodies

All antibodies are commercially available and their specificity has been characterized (32-34) (Table 2). The antibodies included: proNGF polyclonal antiserum (1:50, H-20 [Santa Cruz Biotechnology, Santa Cruz, CA]); purified anti-TrkA rabbit polyclonal affinity-purified antibodies (1:100, Fitzgerald, Acton, MA); anti-NRH2 (1:1000), -sortilin (1:1000) and -p75NTR (1:500) obtained from Abcam (Cambridge, MA); and anti-Akt (1:1000), phospho-Akt (Ser473) (1:1000), p44/p42 MAPK (Erk1/2) (1:1000), phospho-p44/p42 MAPK (Erk1/2) (Thr202/Tyr 204) (E10) mouse monoclonal antibody (mAb) (1:2000),
SAPK/JNK (56G8) rabbit mAb (1:1000), and phospho-SAPK/JNK(Thr183/Tyr185) (81E11) rabbit mAb (1:2000) obtained from Cell Signaling Technology (Danvers, MA). The loading control β-tubulin mAb (1:4000) was from Millipore (Bedford, MA).

**Quantitative Immunoblotting**

Briefly, sample proteins were denatured in sodium dodecyl sulfate (SDS) loading buffer to a final concentration of 5 mg/ml. Proteins (50 μg/sample) were separated by 8%-16% or 7.5% SDS polyacrylamide gel electrophoresis (Lonza, Rockland, ME) and transferred to polyvinylidene fluoride membranes (Immobilon P; Millipore) electrophoretically as described previously (35-37). Membranes were first blocked in TBS/0.05%Tween-20/5% milk for 60 minutes at room temperature (RT) with the exception of proNGF, which was blocked in 0.5X TBS/0.05% milk for 20 minutes. Phospho-JNK, phospho-Akt and phospho-Erk were blocked in TBS/0.05%Tween-20/3% BSA for 60 minutes. Primary antibodies were added to blocking buffer. After a 60-minute incubation with primary antibodies at RT, membranes were incubated overnight at 4°C. After 3 washes in TBS/0.05% Tween-20, the membranes were incubated for 1 hour at RT with horseradish peroxidase-conjugate goat anti-mouse IgG secondary antibody (1:4000; Pierce, Rockford, IL) or horseradish peroxidase-conjugated goat-anti rabbit IgG secondary antibody (1:4000, Bio-Rad, Hercules, CA). Immunoreactive proteins were visualized by enhanced chemiluminescence (Pierce) on a Kodak Image Station 440CF (Perkin-Elmer, Wellesley, MA). Bands were quantified using Kodak 1D image analysis software. Immunoreactive signals of target proteins were normalized to β-tubulin signals for quantitative analysis. Previously, we verified by immunoblotting, Coomassie blue staining, and densitometry that β-tubulin levels were unchanged in samples from the same clinical diagnostic cohort examined in the present study (36), which is consistent with findings by other groups (38, 39). Therefore, β-tubulin levels were used as the internal control for protein loading. Each sample was analyzed 3 times in independent experiments.

**Sequential Amyloid Extraction and Sandwich Enzyme-linked Immunosorbent Assay for Aβ1-40/Aβ1-42**

The ELISA used for Aβ1-40/Aβ1-42 levels is a modification of a previously described procedure (34). Briefly, hippocampal homogenates were diluted to 10 mg wet weight/ml in homogenization buffer containing protease inhibitors. One mg of crude homogenate was sonicated (30 seconds at 40% Amplification with a 1/8” tapered microtip; Ultrasonic Processor, Fisher Scientific, Pittsburgh, PA) in 10% SDS (final concentration 2% SDS) and centrifuged at 4°C for 1 hour at 100,000 × g (Optima TLX Ultracentrifuge, Beckman-Coulter, Fullerton, CA). Supernatant was collected (SDS-soluble fraction) and the pellet was resuspended in an equal volume of 70% formic acid prepared in water and sonicated again as described above. Formic acid fractions were neutralized to 1:20 dilution in 1.0 M Tris base (pH 11.3). SDS fractions were diluted at least 1:50 and neutralized formic acid fractions were further diluted if needed in ELISA diluent buffer (50 mM Tris base, 150 mM NaCl, 0.5% NP-40, 0.5% deoxycholate, 0.1 mg/ml phenylmethylsulfonyl fluoride, protease inhibitor cocktail, pH 7.4). Fractions were stored at −80°C until ELISA and were not subjected to more than 1 freeze-thaw cycle. Sandwich ELISAs specific for human Aβ1-40 and Aβ1-42 species (EZBRAIN40, EZBRAIN42; EMD Millipore Corporation, Billerica, MA) were performed in duplicate to measure Aβ1-40/Aβ1-42 levels according to the manufacturer’s instructions. Plates were read at 450 nm on a Spectra Max Plus plate reader (Molecular Devices, Sunnyvale, CA).

**Statistical Analysis**

Summary statistics were provided for each variable included in the analyses (mean ± SD, range, frequency, or percentage); β-amyloid data were transformed by taking the natural log.
logarithm in order to reduce data skewness. Clinical, demographic, and neuropathologic characteristics were compared across the clinically defined groups of NCI, MCI, and AD by the Kruskal-Wallis test or Fisher exact test (40), as were the Western blot protein values and ELISA values for β-amyloid. Ad hoc analyses were performed with Bonferroni-type correction for multiple comparisons. Associations between biochemical measures, demographic and clinical characteristics, and neuropathology scores were assessed by Spearman rank correlation (40). Non-parametric methods were used because they are more robust to the effect of outliers and the non-normality in the data. Additional regression analyses were performed as needed to explore the potential confounding effects of clinical variables such as age (41). Due to the large number of proteins examined in this study, factor analyses (42) as well as biological rationale were employed to guide us in our results interpretation; our focus was on the identification of consistent patterns in the data rather than individual comparisons or correlations. Statistical analyses were performed using the SAS software, version 9.2 (SAS Institute Inc). The level of statistical significance was set at 0.05 (2-sided). Results with 0.01 ≤ p-value < 0.05 were interpreted with caution.

RESULTS

Case Demographics

The clinical diagnostic groups did not differ by age, gender, years of education, or postmortem interval (Table 1). There were more subjects with an ApoE 4 allele in the MCI (38%) and AD (31%) groups than in the NCI group (0%) (Table 1). AD cases had lower MMSE scores compared to both MCI and NCI cases (p < 0.0001), whereas the latter 2 groups did not differ statistically (Table 1). GCS and episodic memory z-scores were significantly lower in AD vs. MCI, and in MCI vs. NCI groups. Subjects in the different clinical diagnostic groups displayed considerable heterogeneity with respect to pathological diagnostic criteria. Pathological examination of study subjects revealed that 64% of NCI cases, 85% of MCI cases, and 92% of AD cases were classified as Braak stages III-VI. Using NIA-Reagan criteria, 45% of NCI, 62% of MCI, and 92% of AD cases were classified as intermediate to high likelihood of AD (Table 1). For CERAD diagnosis, 55% of NCI, 69% of MCI, and 100% of AD cases received a diagnosis of probable/definite AD. Statistical analysis revealed a significant difference between the NCI and AD groups for NIA-Reagan (p = 0.042) and CERAD (p = 0.0076) diagnosis, but not for Braak staging.

Hippocampal proNGF, TrkA, p75NTR, Sortilin and NRH2 Receptor Levels

The mean hippocampal proNGF levels were significantly elevated in AD vs. NCI and MCI (by 57% and 41%, respectively; p = 0.004; Fig. 1A). By contrast, mean hippocampal TrkA protein levels were significantly reduced in MCI vs. NCI and AD (by 27% and 36%, respectively; p = 0.014; Fig. 1B). TrkA expression levels in NCI and AD were comparable. There were no significant modifications in hippocampal p75NTR (Fig. 1C), sortilin, or NRH2 (Fig. 1D) expression levels among the 3 clinical groups (Table 3).

Hippocampal Erk and Akt Levels

There were no significant modifications in the expression levels of hippocampal total Erk, phospho-Erk, or their ratio among the 3 clinical groups (Table 3). On the other hand, total Akt levels were reduced from NCI to MCI to AD, whereas phospho-Akt expression levels appeared to be elevated in AD (by ~33%) compared to MCI and NCI (Fig. 2A, B). The ratio of phospho-Akt to Akt was then found to be significantly increased in AD (p = 0.036), though only the difference between AD and MCI reached statistical significance (Fig. 2C).
**Hippocampal JNK and Phospho-JNK Levels**

Although total mean JNK levels remained stable across clinical groups (Table 3; Fig. 3A), phospho-JNK was significantly increased by ~55% in AD vs. NCI and MCI (Fig. 3B; p = 0.0006). The ratio of phospho-JNK to JNK was also similarly increased in AD vs. NCI and MCI (~55%; p = 0.016; Fig. 3C).

**Hippocampal Aβ₁₋₄₀ and Aβ₁₋₄₂ Levels**

Soluble and insoluble derived Aβ₁₋₄₀, Aβ₁₋₄₂ and their ratios remained stable across NCI, MCI and AD groups (Table 4). Analysis revealed a strong positive correlation between hippocampal proNGF and phospho-JNK protein levels (Spearman correlation, r = 0.46, p = 0.0039), and both correlated negatively with cognitive functions as measured by MMSE, GCS, and episodic memory z-score (r = −0.45 to −0.49 and p = 0.0021 to 0.0052 for proNGF, r = −0.33 to −0.44 and p = 0.0072 to 0.049 for phosphor-JNK; Fig. 4). On the other hand, there was a positive correlation between TrkA and the severity of pathology based on Braak, NIA Reagan, and CERAD scores (r = 0.39 to 0.43, p = 0.0050 to 0.011). Moreover, we determined whether protein levels for each variable examined in the present study differed between NCI cases from each cohort when grouped into those with a Braak score I-II (n = 8) vs. III and above (n = 9). Statistical analysis did not reveal differences in any of the protein levels evaluated between early and more advanced Braak stage cases (data not shown).

**DISCUSSION**

Prior studies suggest that mature NGF levels are unchanged in the AD hippocampus compared to aged controls (43, 44), but recent biochemical studies indicate that proNGF is the major form found in the human brain (8). Here we demonstrate a significant increase in hippocampal proNGF expression levels in AD but not in MCI. Notably, proNGF levels were not modified in the MCI hippocampus compared to its up regulation in the neocortex in MCI and AD subjects (33, 45), suggesting that cholinergic forebrain projection groups respond differently during the onset of AD. Interestingly, proNGF isolated from AD cerebral cortex has been shown to induce apoptosis in neuronal cell cultures via an interaction with the p75NTR receptor by a mechanism that is dependent upon γ-secretase shedding of the receptor, whereas proNGF isolated from control brain samples was not able to induce apoptosis (46). Based on the current findings, it is crucial to determine whether the biological actions of proNGF isolated from MCI brain would induce apoptosis similar to that seen in AD samples or whether it acts more like proNGF in controls.

**Hippocampal proNGF Levels During Disease Progression**

Although proNGF binds to p75NTR and its co-receptors sortilin and NRH2, we found no modifications in expression levels of these proteins between clinical groups, which are similar to previous findings in the AD hippocampus (47, 48) and the MCI cortex (49). Sortilin and NRH2 are p75NTR-binding partners, and blocking them precludes the binding of proNGF to p75NTR resulting in cell death (9, 10, 13, 50, 51). In this regard, increasing levels of proNGF and stable levels of p75NTR/sortilin/NRH2 complexes may favor pro-apoptotic signaling in the hippocampus in AD. Interestingly, in vivo models indicate that proNGF is neurotoxic for aged but not young NGF-responsive basal forebrain neurons and that blockade of sortilin rescues proNGF induced cell death (47, 48). Together, these data suggest a molecular link in the brain between normal aging and AD through the regulation of proNGF and its cognate receptors and co-chaperones. In addition, increased proNGF levels also drive alterations in metabolic enzymes such as plasmin and matrix metalloprotease 9 (52), which regulate the maturation and degradation of mature NGF in the extracellular space and are decreased and increased, respectively, in parallel with the
accumulation of proNGF in MCI and AD brains (53). In fact, pharmacologically induced chronic failure in extracellular NGF maturation leads to mature NGF reduction, proNGF accumulation, cholinergic degeneration, and cognitive impairment in rats (54). In the present study, the observed negative correlation between hippocampal proNGF and cognitive function further demonstrates the importance of maintaining homeostatic regulation of the NGF neurotrophic system to cognition during the onset of AD.

**Hippocampal TrkA, p75NTR, Sortilin and NHR2 Levels During Disease Progression**

We found a significant decrease in TrkA expression levels in the MCI hippocampus compared to NCI and AD, suggesting a return to control levels as subjects transition from MCI to AD. Reduction in TrkA in the face of stable proNGF may enhance binding between proNGF and the p75NTR/sortilin/NRH2 complex, potentially shifting away from pro-survival signaling to pro-apoptotic signaling during prodromal AD. The unexpected rebound of TrkA levels in AD hippocampus to control levels indicates yet another example of the resilience of the human brain (4), perhaps in an attempt to stave off or slow the disease processes (7). It is important to note that NGF binding to TrkA reduces, whereas NGF binding to p75NTR activates β-secretase cleavage of the amyloid precursor protein (20, 21), providing a molecular link between neurotrophic signaling in normal brain aging and AD and amyloid processing. Early reduction in hippocampal TrkA may also exacerbate the toxic effects of the amyloid protein during the prodromal stage of AD. However, the increase in TrkA found in AD suggests yet another neuroplastic response to the disease process. In this regard, hippocampal CA1 neuronal TrkB expression is increased in cognitively intact cases displaying early-stage Braak I-II pathology compared with cognitively intact individuals with no NFTs (55). Although we did not find differences in any of the protein levels evaluated when we grouped our NCI cases into Braak stage I-II vs. Braak stage III and above, our cohort did not contain NCI pathology-free cases. Further studies are needed to compare cognitively intact individuals to those with no NFTs, plaques only or pathology-free cases. These observations further suggest that increased trophic factor activity marks brain reserve/resilience throughout the disease process.

We found stable amyloid protein levels in the hippocampus across disease stages, similar to the lack of expression level changes for amyloid precursor protein and its metabolites reported in hippocampal CA1 neurons in MCI and AD (56). However, the harsh treatments needed to extract amyloid for quantitation may contribute to this observation. By contrast, others reported increased Aβ1-42 and Aβ40/42 ratio in the hippocampus of severe AD Braak stage VI cases (57). The severity of NFT pathology in these cases compared to our cohort may explain this difference. Nevertheless, the precise role that amyloid plays, if any, in the activation of neurodegenerative events during the onset of AD awaits further characterization (58).

**Hippocampal Akt and Erk Levels During Disease Progression**

Several downstream kinase-signaling cascades have been identified in NGF/TrkA survival activation (59). We found in AD hippocampus a significant increase in the phospho-Akt to Akt ratio (60), but little difference among 3 clinical groups in their expression levels of hippocampal Erk, phospho-Erk. A recent quantitative immunohistochemical study found an increase in Erk2 pT185/187 in samples taken from the mid-hippocampus of AD compared to NCI cases (60), whereas the present tissue was obtained from the caudal hippocampus. Therefore, these discrepancies may relate to methodological or regional differences. Although the precise biological actions of an increase in phospho-Akt remains a challenging question in AD research, Akt may serve to suppress apoptosis directly by activating several different anti-apoptotic proteins, suppressing GSK3 apoptotic activities, or by blocking the function of the JNK pathway (61). Interestingly, in vivo findings also indicate that p75NTR
can activate Akt via a phosphatidylinositol 3-kinase pathway which facilitates cell survival (62). These observations suggest that Akt mediates cell survival at a number of levels, depending upon target availability and the requirement for transcriptional or post-transcriptional events to suppress apoptosis.

**Hippocampal JNK Levels During Disease Progression**

Although proNGF upstream receptor binding initiates downstream JNK apoptotic signaling (63), we found that JNK remained stable across clinical groups. However, phospho-JNK and the ratio of phospho-JNK to JNK were significantly increased in AD compared to NCI and MCI. The increase in phospho-JNK may reflect a chronic and accumulative stress process that builds during the disease process and may be a very early marker for neuronal degeneration as it is associated with neurofibrillary alteration in some elderly controls (64). In the transition from MCI to AD, hippocampal phospho-JNK activation occurs in the face of increased levels of proNGF and phospho-Akt and reduced level of TrkA, despite no change in amyloidoid level. This suggests that increasing TrkA and phospho-Akt in AD might offset a shift toward JNK-mediated apoptotic signaling in AD. Similar to proNGF, we found that higher hippocampal phospho-JNK levels correlated with lower cognitive test scores, suggesting that pro-apoptotic signaling abnormalities ultimately override the putative compensatory TrkA-mediated pro-survival cascades as the disease progresses.

**Neuropathological and Clinical Correlation with Hippocampal proNGF, Phospho-Akt, and Phospho-JNK during Disease Progression**

When utilizing the Braak scores for NFT number and anatomic distribution and NIA-Reagan criteria for pathological diagnosis, combined with CERAD pathological findings, we found remarkable similarity in the degree of pathology between the MCI and AD groups, although only the AD group displayed an upregulation of hippocampal proNGF, phospho-Akt, and phospho-JNK activity. These data suggest that global AD-like pathology in general does not mediate the increase of these proteins. Of particular interest is the observation that many NCI cases displayed Braak, NIA-Reagan, and CERAD scores similar to that seen in both MCI and AD subjects; this was previously reported also in our other studies using RROS tissue (24, 65) as well as in other MCI populations (66, 67). Moreover, there was a positive correlation between TrkA and severity of pathology. Together the present findings suggest the need to rethink the involvement of classic AD pathology in the early initiation and/or generation of neurotrophic dysfunction in the early stages of AD. Moreover, the negative correlation between proNGF and cognitive function was observed both in the hippocampus and, previously, in the cortex (33). On the other hand, hippocampal TrkA levels did not correlate with cognitive function, whereas cortical TrkA levels were positively correlated with cognitive function (36). These findings suggest that alterations in NGF upstream and downstream signaling are associated with conversion to AD (68-70).

**Summary**

A schematic summary of the present study is presented in Figure 5. Whether alterations in proNGF signaling pathways are a primary event in the pathogenesis of AD or a secondary response to other pathological changes remain unknown. Because we found overlapping plaque and NFT pathology and no modification in the expression levels of Aβ1-40, Aβ1-42 and Aβ40/42 ratio across clinical groups, these degenerative events may not play a direct role in hippocampal neurotrophin dysregulation. In the present study, the positive correlation observed between hippocampal proNGF and phospho-JNK levels, and their negative correlation with cognitive test scores including episodic memory, indicates that hippocampal NGF signaling abnormalities play a pervasive and key role in cognitive impairment during the onset of AD and represent drug targets for the treatment of dementia.
Acknowledgments

The authors declare that they have no conflict of interest. The authors thank the nuns, priests, and brothers from across the country that participated in the Religious Orders Study and Rush Alzheimer’s Disease Center staff. The authors also thank patients and research participants at the University of Kentucky Alzheimer’s Disease Center.

Supported by NIA Grants PO1AG14449, PO1AG9466 and P30AG10161.

REFERENCES


Boxplots and representative immunoblots of hippocampal levels of precursor of nerve growth factor (ProNGF), TrkA, p75 neurotrophin receptor (p75NTR) and neurotrophin receptor homolog-2 (NRH2) in cases clinically diagnosed as no cognitive impairment (NCI), mild cognitive impairment (MCI), and Alzheimer disease (AD). Immunoreactive signals were normalized to β-tubulin levels on the same blots by densitometry. (A) Levels of proNGF were significantly elevated in AD vs. NCI and MCI. *, p = 0.004. (B) Levels of TrkA were significantly reduced in MCI and upregulated in AD. *, p = 0.014. (C, D) Levels of p75NTR (C) and NRH2 (D) remained stable across clinical diagnoses.
Figure 2.
Boxplots of hippocampal levels of Akt, phospho-Akt (p-Akt), and the ratio of p-Akt to Akt in cases clinically diagnosed as no cognitive impairment (NCI), mild cognitive impairment (MCI), and Alzheimer disease (AD). Representative immunoblots for p-Akt and Akt are also presented. (A) Levels of total Akt slightly decreased from NCI to MCI to AD. (B) Levels of p-Akt were increased in AD vs. NCI and MCI, but the difference did not reach statistical significance. (C) The p-Akt to Akt ratio was significantly higher in AD vs. NCI and MCI. *, p = 0.036.
Figure 3.
Boxplots of hippocampal levels of c-jun kinase (JNK), phospho-JNK, and the ratio of phospho-JNK to JNK in cases clinically diagnosed as no cognitive impairment (NCI), mild cognitive impairment (MCI), and Alzheimer disease (AD). Representative immunoblots for phospho-JNK and JNK are also presented. (A) Levels of total JNK remained stable across clinical diagnosis. (B) Levels of phospho-JNK were significantly increased in AD vs. NCI and MCI. *, p = 0.0006. (C) Similar to phospho-JNK, the phospho-JNK to JNK ratio also showed significantly elevated levels in AD vs. MCI and NCI. *, p = 0.016.
Figure 4.
(A-F) Hippocampal precursor of nerve growth factor (proNGF) and phospho-c-jun kinase (JNK) protein levels negatively correlated with cognitive function as measured by Mini-Mental State Examination (MMSE) (A, D), Global Cognitive Score (B, E), and episodic memory z-score (C, F). No cognitive impairment (NCI) = open squares; mild cognitive impairment (MCI) = filled triangles; Alzheimer disease (AD) = open circles.
Figure 5.
Schematic summary diagram showing the relative changes for precursor of nerve growth factor (ProNGF), TrkA, p75 neurotrophin receptor (p75\textsuperscript{NTR}), neurotrophin receptor homolog-2 (NRH2), Erk, Akt, phospho-Akt, c-jun kinase (JNK) and phospho-JNK in the hippocampus during the progression of Alzheimer disease. No cognitive impairment (NCI); mild cognitive impairment (MCI); mild Alzheimer disease (mAD).
<table>
<thead>
<tr>
<th>Clinical Diagnosis</th>
<th>NCI (n=11)</th>
<th>MCI (n=13)</th>
<th>AD (n=13)</th>
<th>Total (n=37)</th>
<th>p value</th>
<th>Pair-wise comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y) at death:</td>
<td>Mean ± SD</td>
<td>83.4 ± 4.6</td>
<td>87.7 ± 5.8</td>
<td>85.6 ± 5.1</td>
<td>0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>(Range)</td>
<td>(76-93)</td>
<td>(76-98)</td>
<td>(76-98)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number (%) of males:</td>
<td>5 (45%)</td>
<td>5 (38%)</td>
<td>6 (46%)</td>
<td>16 (43%)</td>
<td>1.0&lt;sup&gt;b&lt;/sup&gt;</td>
<td>--</td>
</tr>
<tr>
<td>Years of education:</td>
<td>Mean ± SD</td>
<td>17.5 ± 4.7</td>
<td>19.0 ± 3.3</td>
<td>18.1 ± 3.9</td>
<td>0.8&lt;sup&gt;d&lt;/sup&gt;</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>(Range)</td>
<td>(10-25)</td>
<td>(14-26)</td>
<td>(10-26)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number (%) with ApoE ε4 allele:</td>
<td>0</td>
<td>5 (38%)</td>
<td>6 (46%)</td>
<td>16 (43%)</td>
<td>0.058&lt;sup&gt;b&lt;/sup&gt;</td>
<td>--</td>
</tr>
<tr>
<td>MMSE:</td>
<td>Mean ± SD</td>
<td>27.6 ± 1.4</td>
<td>19.9 ± 6.4</td>
<td>24.9 ± 5.5</td>
<td>0.0002&lt;sup&gt;a&lt;/sup&gt;</td>
<td>(NCI, MCI) &gt; AD</td>
</tr>
<tr>
<td></td>
<td>(Range)</td>
<td>(26-30)</td>
<td>(9-28)</td>
<td>(9-30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global Cognitive Score:</td>
<td>Mean ± SD</td>
<td>0.5 ± 0.2</td>
<td>−0.5 ± 0.3</td>
<td>0.0 ± 0.5</td>
<td>&lt;0.0001&lt;sup&gt;a&lt;/sup&gt;</td>
<td>NCI &gt; MCI &gt; AD</td>
</tr>
<tr>
<td></td>
<td>(Range)</td>
<td>(0.2-0.8)</td>
<td>(−0.5, −0.1)</td>
<td>(−1.2, 1.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Episodic Memory Z-score:</td>
<td>Mean ± SD</td>
<td>0.8 ± 0.3</td>
<td>0.6 ± 0.7</td>
<td>0.1 ± 0.8</td>
<td>&lt;0.0001&lt;sup&gt;a&lt;/sup&gt;</td>
<td>NCI &gt; MCI &gt; AD</td>
</tr>
<tr>
<td></td>
<td>(Range)</td>
<td>(0.3, 1.4)</td>
<td>(−0.2, 0.6)</td>
<td>(−2.0, 1.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-mortem interval (hours):</td>
<td>Mean ± SD</td>
<td>5.7 ± 3.3</td>
<td>4.2 ± 1.6</td>
<td>5.1 ± 2.5</td>
<td>0.4&lt;sup&gt;d&lt;/sup&gt;</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>(Range)</td>
<td>(1.4-12.4)</td>
<td>(1.5-7.3)</td>
<td>(1.0-12.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distribution of Braak scores:</td>
<td>I/II</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>7</td>
<td>0.14&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>III/IV</td>
<td>6</td>
<td>8</td>
<td>8</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td></td>
<td>V/VI</td>
<td>1</td>
<td>3</td>
<td>4</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>NIA Reagan diagnosis (likelihood of AD):</td>
<td>No AD</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.042&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Low</td>
<td>6</td>
<td>5</td>
<td>1</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intermediate</td>
<td>5</td>
<td>5</td>
<td>9</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td></td>
<td>High</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>CERAD diagnosis:</td>
<td>No AD</td>
<td>3</td>
<td>4</td>
<td>0</td>
<td>7</td>
<td>0.0076&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Possible</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Probable</td>
<td>6</td>
<td>6</td>
<td>7</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Definite</td>
<td>0</td>
<td>3</td>
<td>6</td>
<td>9</td>
<td></td>
</tr>
</tbody>
</table>

AD = Alzheimer disease; CERAD = Consortium to Establish a Registry for Alzheimer Disease; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; NCI = no cognitive impairment.

*4 of the 13 MCI cases were amnestic MCI.
\[ a \] Kruskal-Wallis test, with Bonferroni correction for multiple comparisons.

\[ b \] Fisher’s exact test, with Bonferroni correction for multiple comparisons.
### Table 2

<table>
<thead>
<tr>
<th>Antibodies</th>
<th>Epitope or Immunogen</th>
<th>Dilution</th>
<th>Company and Catalog #</th>
</tr>
</thead>
<tbody>
<tr>
<td>proNGF</td>
<td>rabbit polyclonal to NGF (H-20)</td>
<td>1:50</td>
<td>Santa Cruz Biotechnology; Santa Cruz, CA # sc-548</td>
</tr>
<tr>
<td>TrkA receptor</td>
<td>rabbit polyclonal to TrkA</td>
<td>1:100</td>
<td>Fitzgerald Industries International, Acton, MA # 20R-TR013</td>
</tr>
<tr>
<td>p75NTR receptor</td>
<td>rabbit polyclonal to p75 NGF receptor</td>
<td>1:500</td>
<td>Abcam; Cambridge, MA # ab38335</td>
</tr>
<tr>
<td>Sortilin</td>
<td>rabbit polyclonal to Sortilin</td>
<td>1:1000</td>
<td>Abcam; # ab16640</td>
</tr>
<tr>
<td>NHR2</td>
<td>rabbit polyclonal to NHR2</td>
<td>1:1000</td>
<td>Abcam; # ab18460 (discontinued)</td>
</tr>
<tr>
<td>Akt</td>
<td>rabbit polyclonal to Akt</td>
<td>1:1000</td>
<td>Cell Signaling Technology, Danvers, MA # 9272</td>
</tr>
<tr>
<td>phospho-Akt</td>
<td>rabbit polyclonal to phospho-Akt</td>
<td>1:1000</td>
<td>Cell Signaling Technology; # 9271</td>
</tr>
<tr>
<td>JNK</td>
<td>rabbit polyclonal to SAPK/JNK (56G8)</td>
<td>1:1000</td>
<td>Cell Signaling Technology; # 9258</td>
</tr>
<tr>
<td>phospho-JNK</td>
<td>rabbit polyclonal to phospho SAPK/ JNK (81E11)</td>
<td>1:2000</td>
<td>Cell Signaling Technology; # 4668</td>
</tr>
<tr>
<td>Erk</td>
<td>rabbit polyclonal to p44/42 MAPK (Erk1/2)</td>
<td>1:1000</td>
<td>Cell Signaling Technology; #9102</td>
</tr>
<tr>
<td>phospho-Erk</td>
<td>mouse monoclonal to phospho p44/42 MAPK (Erk1/2) (E10 clone)</td>
<td>1:2000</td>
<td>Cell Signaling Technology; #9106</td>
</tr>
<tr>
<td>β-tubulin</td>
<td>mouse monoclonal to (KMX-1 clone)</td>
<td>1:4000</td>
<td>Millipore, Billerica, MA # MAB3408</td>
</tr>
</tbody>
</table>

proNGF, precursor of nerve growth factor (ProNGF); p75NTR, p75 neurotrophin receptor; NRH2, neurotrophin receptor homolog-
Table 3

Summary of Hippocampal Protein Levels by Diagnosis Category

<table>
<thead>
<tr>
<th>Clinical Diagnosis</th>
<th>NCI (N=11)</th>
<th>MCI (N=13)</th>
<th>AD (N=13)</th>
<th>Total (N=37)</th>
<th>P-value*</th>
<th>Pair-wise comparison*</th>
</tr>
</thead>
<tbody>
<tr>
<td>ProNGF</td>
<td>0.41 ± 0.10 (0.29-0.56)</td>
<td>0.37 ± 0.09 (0.25-0.58)</td>
<td>0.58 ± 0.15 (0.37-0.88)</td>
<td>0.46 ± 0.15 (0.25-0.88)</td>
<td>0.004</td>
<td>(NCI, MCI) &lt; AD</td>
</tr>
<tr>
<td>TrkA</td>
<td>0.64 ± 0.15 (0.43-0.91)</td>
<td>0.47 ± 0.17 (0.27-0.89)</td>
<td>0.74 ± 0.31 (0.25-1.32)</td>
<td>0.62 ± 0.25 (0.25-1.32)</td>
<td>0.014</td>
<td>(NCI, AD) &gt; MCI</td>
</tr>
<tr>
<td>Phospho-Erk</td>
<td>0.08 ± 0.02 (0.04-0.10)</td>
<td>0.10 ± 0.05 (0.02-0.22)</td>
<td>0.09 ± 0.05 (0.03-0.18)</td>
<td>0.09 ± 0.04 (0.02-0.22)</td>
<td>0.6</td>
<td>--</td>
</tr>
<tr>
<td>Erk</td>
<td>0.82 ± 0.22 (0.32-1.11)</td>
<td>0.86 ± 0.29 (0.38-1.36)</td>
<td>0.90 ± 0.25 (0.48-1.35)</td>
<td>0.86 ± 0.25 (0.32-1.36)</td>
<td>0.7</td>
<td>--</td>
</tr>
<tr>
<td>Erk ratio</td>
<td>0.10 ± 0.03 (0.05-0.15)</td>
<td>0.13 ± 0.10 (0.04-0.33)</td>
<td>0.10 ± 0.04 (0.04-0.16)</td>
<td>0.11 ± 0.07 (0.04-0.33)</td>
<td>0.9</td>
<td>--</td>
</tr>
<tr>
<td>Phospho-Akt</td>
<td>0.28 ± 0.10 (0.13-0.50)</td>
<td>0.26 ± 0.09 (0.12-0.42)</td>
<td>0.36 ± 0.13 (0.16-0.57)</td>
<td>0.30 ± 0.11 (0.12-0.57)</td>
<td>0.1</td>
<td>--</td>
</tr>
<tr>
<td>Akt</td>
<td>1.46 ± 0.22 (1.18-2.00)</td>
<td>1.37 ± 0.38 (1.00-2.36)</td>
<td>1.29 ± 0.39 (0.78-2.27)</td>
<td>1.37 ± 0.34 (0.78-2.36)</td>
<td>0.3</td>
<td>--</td>
</tr>
<tr>
<td>Akt ratio</td>
<td>0.20 ± 0.08 (0.09-0.38)</td>
<td>0.20 ± 0.08 (0.07-0.40)</td>
<td>0.29 ± 0.12 (0.13-0.58)</td>
<td>0.23 ± 0.10 (0.07-0.58)</td>
<td>0.036</td>
<td>MCI &lt; AD</td>
</tr>
<tr>
<td>p75</td>
<td>0.94 ± 0.23 (0.55-1.44)</td>
<td>0.84 ± 0.16 (0.55-1.10)</td>
<td>0.79 ± 0.11 (0.62-0.96)</td>
<td>0.85 ± 0.18 (0.55-1.44)</td>
<td>0.2</td>
<td>--</td>
</tr>
<tr>
<td>Sortilin</td>
<td>3.32 ± 1.72 (1.30-5.63)</td>
<td>2.76 ± 1.03 (0.99-5.09)</td>
<td>3.23 ± 1.56 (0.93-6.39)</td>
<td>3.09 ± 1.43 (0.93-6.39)</td>
<td>0.8</td>
<td>--</td>
</tr>
<tr>
<td>NRH2 **</td>
<td>0.07 ± 0.06 (0.02-0.23)</td>
<td>0.08 ± 0.06 (0.02-0.19)</td>
<td>0.08 ± 0.05 (0.04-0.21)</td>
<td>0.07 ± 0.06 (0.02-0.23)</td>
<td>0.5</td>
<td>--</td>
</tr>
<tr>
<td>Phospho-JNK</td>
<td>0.08 ± 0.04 (0.04-0.16)</td>
<td>0.09 ± 0.02 (0.05-0.12)</td>
<td>0.13 ± 0.02 (0.09-0.17)</td>
<td>0.10 ± 0.04 (0.04-0.17)</td>
<td>0.0006</td>
<td>(NCI, MCI) &lt; AD</td>
</tr>
<tr>
<td>JNK</td>
<td>0.72 ± 0.24 (0.17-1.08)</td>
<td>0.64 ± 0.16 (0.41-0.98)</td>
<td>0.66 ± 0.26 (0.28-1.22)</td>
<td>0.67 ± 0.22 (0.17-1.22)</td>
<td>0.5</td>
<td>--</td>
</tr>
<tr>
<td>JNK ratio</td>
<td>0.13 ± 0.08 (0.04-0.27)</td>
<td>0.15 ± 0.05 (0.06-0.25)</td>
<td>0.22 ± 0.08 (0.09-0.35)</td>
<td>0.17 ± 0.08 (0.04-0.35)</td>
<td>0.016</td>
<td>(NCI, MCI) &lt; AD</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD (range).

NCI = no cognitive impairment; MCI = mild cognitive impairment; AD = Alzheimer disease; proNGF = precursor form of nerve growth factor; JNK = c-jun kinase.

* Kruskal-Wallis test, with Bonferroni correction for multiple comparisons.

** NRH2 data was obtained from a subset of ROS cases (5 NCI, 4 MCI, 4 AD) and additional UKADC cases (7 NCI, 5 MCI, 3 AD).
Table 4

Summary of Hippocampal Amyloid Load by Diagnosis Category

<table>
<thead>
<tr>
<th>Clinical Diagnosis</th>
<th>SDS 42 (N=11)</th>
<th>MCI (N=13)</th>
<th>AD (N=13)</th>
<th>Total (N=37)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ± SD (range)</td>
<td>Mean ± SD (range)</td>
<td>Mean ± SD (range)</td>
<td>Mean ± SD (range)</td>
<td></td>
</tr>
<tr>
<td>SDS 2</td>
<td>8.39 ± 1.13 (6.55-9.88)</td>
<td>9.27 ± 1.11 (6.71-11.49)</td>
<td>9.00 ± 0.82 (7.82-10.29)</td>
<td>8.94 ± 1.04 (6.55-11.49)</td>
<td>0.1</td>
</tr>
<tr>
<td>SDS 2</td>
<td>5.43 ± 0.80 (4.73-7.59)</td>
<td>5.36 ± 0.58 (4.37-6.43)</td>
<td>5.45 ± 0.43 (4.73-6.16)</td>
<td>5.43 ± 0.62 (4.37-7.59)</td>
<td>0.7</td>
</tr>
<tr>
<td>SDS 2/40 ratio</td>
<td>2.96 ± 1.34 (0.17-4.24)</td>
<td>3.92 ± 1.05 (1.60-5.71)</td>
<td>3.55 ± 0.71 (2.43-4.75)</td>
<td>3.51 ± 1.08 (0.17-5.71)</td>
<td>0.2</td>
</tr>
<tr>
<td>FA 2</td>
<td>9.13 ± 1.33 (7.20-11.17)</td>
<td>8.43 ± 2.33 (4.23-12.31)</td>
<td>9.03 ± 1.68 (5.96-10.59)</td>
<td>8.96 ± 1.80 (4.23-12.31)</td>
<td>0.6</td>
</tr>
<tr>
<td>FA 2/40 ratio</td>
<td>2.83 ± 1.56 (−0.82, 4.85)</td>
<td>2.25 ± 1.69 (−1.52, 4.29)</td>
<td>2.92 ± 1.24 (1.07-4.75)</td>
<td>2.66 ± 1.48 (−1.52, 4.85)</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Mean ± SD (range).

SDS = sodium dodecyl sulfate-soluble fractions; FA = formic acid fractions.

*All values were log-transformed so these summary statistics were less skewed by the non-normality in the data.

**After exclusion of one outlier: 5.21 ± 0.38 (4.73-5.88).

**After exclusion of one outlier: 3.24 ± 1.02 (1.34-4.24).